Clinical trials: Spinal Fusion
Degenerative Disc Disease
Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease
Subjects in whom a posterolateral fusion surgery has been planned and who meet the inclusion and exclusion criteria were proposed to receive a single-dose AMSC treatment, in order to assess its safety and efficacy on…
- Trial name
- AMSC-DSD-001 (NCT03827096)
- Testing
- Suspension of human autologous MSC 3P in 1.5 ml
- Volunteers
- 10 people
- Sponsor
- Bioinova, s.r.o.